Brief: Akari Therapeutics Receives Positive Opinion On Orphan Drug Designation From The European Medicines Agency For Nomacopan For Treatment In Hematopoietic Stem Cell Transplantation

Akari Therapeutics

06/07/2023 13:17

July 6 (Reuters) - Akari Therapeutics PLC  AKTX.O :
    * AKARI THERAPEUTICS RECEIVES POSITIVE OPINION ON ORPHAN
DRUG
DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR NOMACOPAN FOR
TREATMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
    * AKARI THERAPEUTICS PLC - CURRENTLY CONDUCTING A
REGISTRATIONAL
PHASE 3 CLINICAL TRIAL OF NOMACOPAN IN PEDIATRIC HSCT-TMA
    * AKARI THERAPEUTICS PLC -  IF ORPHAN DRUG STATUS
DESIGNATION IS
GRANTED, AKARI WILL RECEIVE SCIENTIFIC ADVICE TAILORED FOR
ORPHAN DRUGS
    * AKARI THERAPEUTICS PLC - IF A REGULATORY FILING IS
APPROVED,
AKARI ALSO WOULD RECEIVE EXTENDED MARKET EXCLUSIVITY

Source text for Eikon:  ID:nGNE36mQsN 
Further company coverage:  AKTX.O 

 ((reuters.briefs@thomsonreuters.com;))